Affordable Access

deepdyve-link
Publisher Website

Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.

Authors
  • Weidlich, Diana1
  • Andersson, Fredrik L2, 3
  • Oelke, Matthias4
  • Drake, Marcus John5
  • Jonasson, Aino Fianu6
  • Guest, Julian F7, 8
  • 1 Catalyst Health Economics Consultants, 34b High Street, Northwood, Middlesex, HA6 1BN, UK.
  • 2 Ferring Pharmaceuticals, Copenhagen, Denmark. , (Denmark)
  • 3 Center for Medical Technology Assessment (CMT), Linköping University, Linköping, Sweden. , (Sweden)
  • 4 Department of Urology, Hanover Medical School, Hannover, Germany. , (Germany)
  • 5 Bristol Urological Institute, Bristol, UK.
  • 6 Division of Obstetrics and Gynaecology, CLINTEC, Karolinska Institutet, Stockholm, Sweden. , (Sweden)
  • 7 Catalyst Health Economics Consultants, 34b High Street, Northwood, Middlesex, HA6 1BN, UK. [email protected]
  • 8 Faculty of Life Sciences and Medicine, King's College, London, UK. [email protected]
Type
Published Article
Journal
The European journal of health economics : HEPAC : health economics in prevention and care
Publication Date
Jul 01, 2017
Volume
18
Issue
6
Pages
761–771
Identifiers
DOI: 10.1007/s10198-016-0826-x
PMID: 27678109
Source
Medline
Keywords
License
Unknown

Abstract

Nocturia appears to impose a substantial socioeconomic burden in all three countries. Clinical and economic benefits could accrue from an increased awareness of the impact that nocturia imposes on patients, health services, and society as a whole.

Report this publication

Statistics

Seen <100 times